Methods of use and efficacy of targeted drugs for renal cancer

Renal cell carcinoma is highly resistant to radiotherapy and chemotherapy. Immunotherapy is the standard treatment for metastatic renal cell carcinoma (MRCC), but its efficacy is very limited. The advent of molecular targeted drugs has greatly improved this situation. In recent years, with the in-depth research and the continuous emergence of new molecular targeted drugs, the treatment of tumors has entered the era of molecular targeting.

Pharmacological action: Sunitinib malate capsules can inhibit multiple receptor tyrosine kinases (RTKs), some of which are involved in tumor growth, pathological angiogenesis and tumor metastasis. Sunitinib malate capsules have inhibitory effects on the activities of platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factor (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase 3 (FLT3), colony stimulating factor receptor type 1 (CSF-1R) and glial cell-derived neurotrophic factor receptor (RET), and its main metabolites have similar activities to sunitinib malate.
Dosage and Administration: The recommended dose for the treatment of advanced renal cell carcinoma is 50 mg, once a day, orally; take the drug for 4 weeks and stop for 2 weeks (4/2 dosing regimen). It can be taken with or without food.
Efficacy: Generally speaking, it is effective for about 90% of kidney cancer patients. Among the effective patients, a few patients can make the lesions disappear, and some patients can make the lesions smaller or the tumors remain stable during the medication process. Adverse reactions: The most common: fatigue, loss of appetite, nausea, diarrhea, some patients may also have leukopenia and thrombocytopenia, hand-foot syndrome, etc. Most adverse reactions are not serious and can be treated.